Edition:
United States

Evoke Pharma Inc (EVOK.OQ)

EVOK.OQ on NASDAQ Stock Exchange Capital Market

2.54USD
12:51pm EST
Change (% chg)

$-0.01 (-0.39%)
Prev Close
$2.55
Open
$2.51
Day's High
$2.55
Day's Low
$2.45
Volume
7,879
Avg. Vol
17,045
52-wk High
$3.40
52-wk Low
$1.86

Latest Key Developments (Source: Significant Developments)

Evoke Pharma Reports Third Quarter 2018 Results
Tuesday, 13 Nov 2018 04:05pm EST 

Nov 13 (Reuters) - Evoke Pharma Inc ::EVOKE PHARMA REPORTS THIRD QUARTER 2018 RESULTS.Q3 LOSS PER SHARE $0.09.Q3 EARNINGS PER SHARE VIEW $-0.08 -- THOMSON REUTERS I/B/E/S.AS OF SEPTEMBER 30, 2018, CASH AND CASH EQUIVALENTS WERE APPROXIMATELY $6.6 MILLION.  Full Article

Evoke Pharma Q2 Loss Per Share $0.14
Thursday, 9 Aug 2018 04:05pm EDT 

Evoke Pharma Inc ::EVOKE PHARMA REPORTS SECOND QUARTER 2018 RESULTS AND RECENT HIGHLIGHTS.Q2 LOSS PER SHARE $0.14.Q2 EARNINGS PER SHARE VIEW $-0.17 -- THOMSON REUTERS I/B/E/S.ANTICIPATE RECEIPT OF 74-DAY FDA FILING COMMUNICATION LETTER IN MID-AUGUST AND ASSIGNMENT OF PDUFA GOAL DATE.  Full Article

Evoke Pharma Q4 Loss Per Share $0.02
Wednesday, 7 Mar 2018 04:05pm EST 

March 7 (Reuters) - Evoke Pharma Inc ::EVOKE PHARMA REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND RECENT HIGHLIGHTS.Q4 LOSS PER SHARE $0.02.INCLUDED IN NET LOSS FOR Q4 OF 2017 WAS GAIN OF ABOUT $2.3 MILLION DUE TO CHANGE IN FAIR VALUE OF WARRANT LIABILITY.AS OF DECEMBER 31, 2017, CO'S CASH AND CASH EQUIVALENTS WERE APPROXIMATELY $7.7 MILLION.  Full Article

FDA Approves PDUFA Fee Waiver For Gimoti New Drug Application
Monday, 5 Mar 2018 07:30am EST 

March 5 (Reuters) - Evoke Pharma Inc ::FDA APPROVES PDUFA FEE WAIVER FOR GIMOTI™ NEW DRUG APPLICATION.FDA GRANTED ITS REQUEST FOR SMALL BUSINESS WAIVER OF PDUFA FEE OF ABOUT $2.4 MILLION FOR ITS TREATMENT GIMOTI.COMPANY REMAINS ON TRACK TO FILE GIMOTI NDA NEXT QUARTER.LOOK FORWARD TO POTENTIAL U.S. PRODUCT LAUNCH IN 2019 OF GIMOTI.AS CO REVIEWS 2018 BUDGET, ABLE TO EXTEND CASH RUNWAY INTO OCTOBER 2018.  Full Article

Evoke Pharma Announces Discovery Of Sex-Based Pharmacokinetic Differences For Gimoti​
Thursday, 15 Feb 2018 07:30am EST 

Feb 15 (Reuters) - Evoke Pharma Inc ::EVOKE PHARMA INC - ‍EVOKE ANNOUNCES DISCOVERY OF SEX-BASED PHARMACOKINETIC DIFFERENCES FOR GIMOTI​.EVOKE PHARMA - ANALYSIS OF PK DATA BY SEX REVEALED STATISTICALLY SIGNIFICANT DIFFERENCES IN EXPOSURE BETWEEN WOMEN & MEN GIVEN SAME METOCLOPRAMIDE DOSE​.EVOKE PHARMA INC - ‍COMPANY HAS FILED NEW PATENT APPLICATIONS RELATED TO DISCOVERY​.EVOKE PHARMA INC - ‍COMPANY NOW EXPECTS TO FILE GIMOTI NDA IN Q2 OF 2018​.  Full Article

Evoke Pharma reports Q3 loss per share $0.34
Tuesday, 14 Nov 2017 04:05pm EST 

Nov 14 (Reuters) - Evoke Pharma Inc ::Evoke Pharma reports third quarter 2017 results and highlights.Q3 loss per share $0.34.Q3 earnings per share view $-0.20 -- Thomson Reuters I/B/E/S.  Full Article

Evoke Pharma signs commercial agreement with Thermo Fisher Scientific
Thursday, 9 Nov 2017 08:30am EST 

Nov 9 (Reuters) - Evoke Pharma Inc ::Signs commercial agreement with Thermo Fisher Scientific.Announced selection of Patheon division of Thermo Fisher Scientific as commercial manufacturing partner for Gimoti​.Under five-year agreement, Thermo Fisher will manufacture Gimoti for Evoke's potential commercial efforts​.  Full Article

Evoke Pharma reports positive topline results from comparative exposure pharmacokinetic study for gimoti
Monday, 23 Oct 2017 07:30am EDT 

Oct 23 (Reuters) - Evoke Pharma Inc ::Evoke Pharma announces positive topline results from comparative exposure pharmacokinetic study for gimoti™.Evoke Pharma- co will submit a 505(b)(2) NDA with a selected gimoti dose to the U.S. FDA in Q1 of 2018​.Evoke Pharma Inc- ‍relative to safety, all gimoti doses were well‑tolerated.  Full Article

Evoke Pharma reports Q2 loss per share $0.11
Monday, 14 Aug 2017 04:05pm EDT 

Aug 14 (Reuters) - Evoke Pharma Inc -:Evoke Pharma reports second quarter 2017 results and highlights.Q2 loss per share $0.11.Q2 earnings per share view $-0.15 -- Thomson Reuters I/B/E/S.  Full Article

Evoke pharma inc initiates comparative exposure Pharmacokinetic Study for Gimoti
Monday, 14 Aug 2017 08:30am EDT 

Aug 14 (Reuters) - Evoke Pharma Inc :Evoke Pharma Inc - ‍initiation of its comparative exposure Pharmacokinetic trial for Gimoti​.Evoke Pharma - ‍expects to complete analysis of trial data, announce results in Q4 2017, followed by potential nda submission in late 2017 or early 2018​.  Full Article